What is Nu Skin Enter's earnings per share (EPS)?

Nu Skin Enter (NUS) reported diluted earnings per share of $3.18 for fiscal year 2025. This represents a 207.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Nu Skin Enter Financials

NUS

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Nu Skin Enter (NUS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 18 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 44/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Nu Skin Enter has an operating margin of 4.4%, meaning the company retains $4 of operating profit per $100 of revenue. This results in a moderate score of 32/100, indicating healthy but not exceptional operating efficiency. This is up from -8.8% the prior year.

Growth

Nu Skin Enter's revenue declined 14.3% year-over-year, from $1.7B to $1.5B. This contraction results in a growth score of 10/100.

Leverage

Nu Skin Enter carries a low D/E ratio of 0.25, meaning only $0.25 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Nu Skin Enter's current ratio of 2.08 indicates adequate short-term liquidity, earning a score of 38/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Nu Skin Enter has a free cash flow margin of 3.1%, earning a moderate score of 33/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Nu Skin Enter's ROE of 19.9% shows moderate profitability relative to equity, earning a score of 55/100. This is up from -22.5% the prior year.

Altman Z-Score Safe

3.66

Nu Skin Enter scores 3.66, well above the 2.99 safe threshold. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Strong

7/9

Nu Skin Enter passes 7 of 9 financial strength tests. 3 of 4 profitability signals pass, all 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Mixed

0.50x

For every $1 of reported earnings, Nu Skin Enter generates $0.50 in operating cash flow ($80.3M OCF vs $160.2M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage Adequate

4.7x

Nu Skin Enter earns $4.7 in operating income for every $1 of interest expense ($65.8M vs $13.9M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.5B

YoY-14.3%

5Y CAGR-10.5%

10Y CAGR-4.1%

Nu Skin Enter generated $1.5B in revenue in fiscal year 2025. This represents a decrease of 14.3% from the prior year.

EBITDA

$118.0M

YoY+244.3%

5Y CAGR-18.7%

10Y CAGR-9.4%

Nu Skin Enter's EBITDA was $118.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 244.3% from the prior year.

Net Income

$160.2M

YoY+209.3%

5Y CAGR-3.5%

10Y CAGR+1.9%

Nu Skin Enter reported $160.2M in net income in fiscal year 2025. This represents an increase of 209.3% from the prior year.

EPS (Diluted)

$3.18

YoY+207.8%

5Y CAGR-2.6%

10Y CAGR+3.5%

Nu Skin Enter earned $3.18 per diluted share (EPS) in fiscal year 2025. This represents an increase of 207.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$46.0M

YoY-34.4%

5Y CAGR-32.0%

10Y CAGR-16.1%

Nu Skin Enter generated $46.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 34.4% from the prior year.

Cash & Debt

$238.6M

YoY+27.7%

5Y CAGR-9.9%

10Y CAGR-1.9%

Nu Skin Enter held $238.6M in cash against $204.2M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

48M

YoY-3.2%

5Y CAGR-1.1%

10Y CAGR-1.5%

Nu Skin Enter had 48M shares outstanding in fiscal year 2025. This represents a decrease of 3.2% from the prior year.

Margins & Returns

Gross Margin

69.5%

YoY+1.2pp

5Y CAGR-5.1pp

10Y CAGR-8.8pp

Nu Skin Enter's gross margin was 69.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.2 percentage points from the prior year.

Operating Margin

4.4%

YoY+13.2pp

5Y CAGR-5.5pp

10Y CAGR-6.5pp

Nu Skin Enter's operating margin was 4.4% in fiscal year 2025, reflecting core business profitability. This is up 13.2 percentage points from the prior year.

Net Margin

10.8%

YoY+19.3pp

5Y CAGR+3.4pp

10Y CAGR+4.9pp

Nu Skin Enter's net profit margin was 10.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 19.3 percentage points from the prior year.

Return on Equity

19.9%

YoY+42.4pp

5Y CAGR-1.5pp

10Y CAGR+3.8pp

Nu Skin Enter's ROE was 19.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 42.4 percentage points from the prior year.

Capital Allocation

R&D Spending

$10.8M

YoY-16.9%

5Y CAGR-14.3%

10Y CAGR-6.0%

Nu Skin Enter invested $10.8M in research and development in fiscal year 2025. This represents a decrease of 16.9% from the prior year.

Share Buybacks

$20.0M

5Y CAGR-32.6%

10Y CAGR-19.0%

Nu Skin Enter spent $20.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

$34.3M

YoY-17.6%

5Y CAGR-11.7%

10Y CAGR-4.9%

Nu Skin Enter invested $34.3M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 17.6% from the prior year.

NUS Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$1.5B-14.3%	$1.7B-12.0%	$2.0B-11.5%	$2.2B-17.4%	$2.7B+4.4%	$2.6B
Cost of Revenue	$453.8M-17.5%	$550.2M-10.1%	$611.9M-3.0%	$630.9M-6.6%	$675.2M+2.6%	$658.0M
Gross Profit	$1.0B-12.7%	$1.2B-12.9%	$1.4B-14.9%	$1.6B-21.1%	$2.0B+5.0%	$1.9B
R&D Expenses	$10.8M-16.9%	$13.0M-42.5%	$22.6M-3.0%	$23.3M-14.3%	$27.2M+16.7%	$23.3M
SG&A Expenses	$432.1M-9.8%	$479.0M-12.4%	$546.9M-1.6%	$555.8M-15.1%	$654.4M+2.8%	$636.5M
Operating Income	$65.8M+143.4%	-$151.6M-414.0%	$48.3M-56.5%	$110.8M-52.6%	$234.0M-9.2%	$257.6M
Interest Expense	$13.9M-47.2%	$26.4M+3.2%	$25.6M+89.6%	$13.5M+22.7%	$11.0M-16.0%	$13.1M
Income Tax	$36.0M+226.5%	-$28.5M-258.2%	$18.0M+213.8%	-$15.8M-118.6%	$85.2M+31.3%	$64.9M
Net Income	$160.2M+209.3%	-$146.6M-1805.6%	$8.6M-91.8%	$104.8M-28.9%	$147.3M-23.0%	$191.4M
EPS (Diluted)	$3.18+207.8%	$-2.95-1835.3%	$0.17-91.8%	$2.07-27.6%	$2.86-21.2%	$3.63

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$370.3M+1.7%	$364.2M-5.7%	$386.1M+5.9%	$364.5M-18.2%	$445.6M+3.6%	$430.1M-2.0%	$439.1M+5.2%	$417.3M
Cost of Revenue	$108.3M+0.8%	$107.5M-10.7%	$120.4M+2.4%	$117.5M-29.4%	$166.4M+29.3%	$128.7M-2.4%	$131.9M+7.0%	$123.2M
Gross Profit	$262.0M+2.0%	$256.7M-3.4%	$265.7M+7.6%	$247.0M-11.5%	$279.1M-7.4%	$301.5M-1.9%	$307.2M+4.5%	$294.1M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$107.4M+2.5%	$104.8M-1.8%	$106.7M-5.7%	$113.2M-6.4%	$120.9M+4.6%	$115.6M-2.0%	$117.9M-5.3%	$124.6M
Operating Income	$23.2M+7.4%	$21.6M-29.7%	$30.8M+410.8%	-$9.9M+81.3%	-$53.1M-391.2%	$18.2M+114.5%	-$125.6M-1523.2%	$8.8M
Interest Expense	$4.0M-3.6%	$4.1M+64.1%	$2.5M-23.1%	$3.3M-44.0%	$5.9M-9.8%	$6.5M-3.3%	$6.7M-8.3%	$7.3M
Income Tax	$3.7M+441.0%	-$1.1M-117.2%	$6.3M-76.8%	$27.1M+224.8%	-$21.7M-534.3%	$5.0M+137.3%	-$13.4M-919.5%	$1.6M
Net Income	$14.5M-15.2%	$17.1M-19.1%	$21.1M-80.4%	$107.5M+397.8%	-$36.1M-534.9%	$8.3M+107.0%	-$118.3M-22087.2%	-$533K
EPS (Diluted)	N/A	$0.34-20.9%	$0.43-79.9%	$2.14	N/A	$0.17+107.1%	$-2.38-23700.0%	$-0.01

NUS Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$1.4B-4.3%	$1.5B-18.8%	$1.8B-0.7%	$1.8B-4.5%	$1.9B-2.6%	$2.0B
Current Assets	$547.7M+1.7%	$538.6M-23.3%	$701.9M-7.6%	$759.9M-13.0%	$873.0M-3.3%	$903.2M
Cash & Equivalents	$238.6M+27.7%	$186.9M-27.0%	$256.1M-3.3%	$264.7M-22.0%	$339.6M-15.7%	$402.7M
Inventory	$178.6M-6.1%	$190.2M-32.1%	$280.0M-19.1%	$346.2M-13.4%	$399.9M+27.2%	$314.4M
Accounts Receivable	$39.5M-22.1%	$50.8M-13.5%	$58.7M+23.9%	$47.4M+14.7%	$41.3M-34.8%	$63.4M
Goodwill	$83.6M0.0%	$83.6M-61.7%	$218.2M+5.7%	$206.4M0.0%	$206.4M+1.7%	$203.0M
Total Liabilities	$600.1M-26.6%	$817.5M-17.1%	$986.7M+6.8%	$923.7M-7.0%	$993.7M-6.5%	$1.1B
Current Liabilities	$263.7M-11.1%	$296.6M-9.8%	$328.9M-8.5%	$359.2M-32.2%	$529.7M-2.4%	$542.9M
Long-Term Debt	$204.2M-43.8%	$363.6M-23.9%	$478.0M+26.6%	$377.5M+40.4%	$268.8M-12.0%	$305.4M
Total Equity	$805.2M+23.6%	$651.5M-20.7%	$822.0M-8.4%	$897.3M-1.7%	$912.8M+2.1%	$894.3M
Retained Earnings	$1.9B+8.7%	$1.7B-8.5%	$1.9B-3.6%	$1.9B+1.5%	$1.9B+3.9%	$1.8B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$1.4B-1.3%	$1.4B-1.3%	$1.4B+3.8%	$1.4B-5.3%	$1.5B-7.2%	$1.6B-0.2%	$1.6B-9.0%	$1.7B
Current Assets	$547.7M-0.1%	$548.1M-4.1%	$571.6M+8.9%	$524.9M-2.6%	$538.6M-17.6%	$653.4M-0.2%	$654.4M+1.1%	$647.3M
Cash & Equivalents	$238.6M-5.2%	$251.8M-4.7%	$264.2M+29.6%	$203.8M+9.0%	$186.9M-17.9%	$227.8M+1.6%	$224.3M+5.5%	$212.5M
Inventory	$178.6M+0.1%	$178.5M-1.0%	$180.4M-4.4%	$188.8M-0.8%	$190.2M-23.2%	$247.8M+1.6%	$244.0M-8.0%	$265.1M
Accounts Receivable	$39.5M-19.1%	$48.9M-18.1%	$59.7M+5.5%	$56.6M+11.4%	$50.8M-26.2%	$68.8M-3.8%	$71.6M+6.7%	$67.0M
Goodwill	$83.6M0.0%	$83.6M0.0%	$83.6M0.0%	$83.6M0.0%	$83.6M-16.3%	$99.9M0.0%	$99.9M-56.7%	$230.8M
Total Liabilities	$600.1M-3.9%	$624.6M-4.8%	$655.9M+2.9%	$637.4M-22.0%	$817.5M-6.7%	$876.0M-2.6%	$899.8M-3.4%	$931.7M
Current Liabilities	$263.7M+3.7%	$254.4M-10.4%	$283.9M+9.1%	$260.3M-12.2%	$296.6M-12.6%	$339.4M+10.0%	$308.6M-0.2%	$309.3M
Long-Term Debt	$204.2M-2.3%	$209.0M-2.3%	$213.9M-2.2%	$218.8M-39.8%	$363.6M-2.6%	$373.5M-12.8%	$428.3M-5.5%	$453.2M
Total Equity	$805.2M+0.7%	$799.8M+1.5%	$787.8M+4.5%	$754.0M+15.7%	$651.5M-7.8%	$706.9M+3.0%	$686.2M-15.3%	$810.2M
Retained Earnings	$1.9B+0.6%	$1.8B+0.8%	$1.8B+1.0%	$1.8B+6.1%	$1.7B-2.2%	$1.8B+0.3%	$1.7B-6.5%	$1.9B

NUS Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$80.3M-28.2%	$111.7M-5.8%	$118.6M+9.8%	$108.1M-23.7%	$141.6M-62.7%	$379.1M
Capital Expenditures	$34.3M-17.6%	$41.6M-28.9%	$58.5M-1.0%	$59.1M-13.9%	$68.6M+7.5%	$63.8M
Free Cash Flow	$46.0M-34.4%	$70.2M+16.6%	$60.1M+22.7%	$49.0M-32.8%	$73.0M-76.9%	$315.3M
Investing Cash Flow	$170.7M+549.6%	-$38.0M+71.8%	-$134.5M-100.5%	-$67.1M+24.4%	-$88.7M-11.7%	-$79.4M
Financing Cash Flow	-$202.4M-52.0%	-$133.2M-1341.2%	$10.7M+110.8%	-$99.5M+5.0%	-$104.7M+57.3%	-$245.2M
Dividends Paid	$11.8M-0.8%	$11.9M-84.6%	$77.6M+0.8%	$77.0M+1.0%	$76.3M-2.7%	$78.4M
Share Buybacks	$20.0M	$0-100.0%	$13.0M-81.4%	$70.0M-12.9%	$80.4M-44.3%	$144.3M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$16.6M-39.5%	$27.5M-23.2%	$35.8M+9101.8%	$389K-98.5%	$25.8M-18.0%	$31.4M-38.6%	$51.2M+1443.3%	$3.3M
Capital Expenditures	$10.8M+8.5%	$9.9M+54983.3%	$18K-99.9%	$13.6M+8.0%	$12.6M+46.4%	$8.6M+5.8%	$8.1M-33.9%	$12.3M
Free Cash Flow	$5.9M-66.6%	$17.6M-50.9%	$35.8M+371.1%	-$13.2M-199.9%	$13.2M-42.2%	$22.8M-47.0%	$43.1M+580.7%	-$9.0M
Investing Cash Flow	-$9.8M+1.6%	-$9.9M-212.8%	$8.8M-95.2%	$181.5M+1432.7%	-$13.6M-108.1%	-$6.5M+23.3%	-$8.5M+7.9%	-$9.3M
Financing Cash Flow	-$18.5M+31.2%	-$26.9M-390.0%	$9.3M+105.6%	-$166.3M-281.2%	-$43.6M-51.6%	-$28.8M+0.1%	-$28.8M+9.8%	-$32.0M
Dividends Paid	$2.9M-1.9%	$3.0M-0.1%	$3.0M-1.3%	$3.0M+0.6%	$3.0M0.0%	$3.0M0.0%	$3.0M+0.1%	$3.0M
Share Buybacks	$10.0M+100.1%	$5.0M	$0-100.0%	$5.0M	$0	$0	$0	$0

NUS Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	69.5%+1.2pp	68.2%-0.7pp	68.9%-2.7pp	71.7%-3.3pp	75.0%+0.4pp	74.5%
Operating Margin	4.4%+13.2pp	-8.8%-11.2pp	2.5%-2.5pp	5.0%-3.7pp	8.7%-1.3pp	10.0%
Net Margin	10.8%+19.3pp	-8.5%-8.9pp	0.4%-4.3pp	4.7%-0.8pp	5.5%-1.9pp	7.4%
Return on Equity	19.9%+42.4pp	-22.5%-23.6pp	1.1%-10.6pp	11.7%-4.5pp	16.1%-5.3pp	21.4%
Return on Assets	11.4%+21.4pp	-10.0%-10.5pp	0.5%-5.3pp	5.8%-2.0pp	7.7%-2.1pp	9.8%
Current Ratio	2.08+0.3	1.82-0.3	2.13+0.0	2.12+0.5	1.65-0.0	1.66
Debt-to-Equity	0.25-0.3	0.56-0.0	0.58+0.2	0.42+0.1	0.29-0.0	0.34
FCF Margin	3.1%-1.0pp	4.0%+1.0pp	3.0%+0.9pp	2.2%-0.5pp	2.7%-9.5pp	12.2%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	70.7%+0.3pp	70.5%+1.7pp	68.8%+1.1pp	67.8%+5.1pp	62.6%-7.4pp	70.1%+0.1pp	70.0%-0.5pp	70.5%
Operating Margin	6.3%+0.3pp	5.9%-2.0pp	8.0%+10.7pp	-2.7%+9.2pp	-11.9%-16.2pp	4.2%+32.8pp	-28.6%-30.7pp	2.1%
Net Margin	3.9%-0.8pp	4.7%-0.8pp	5.5%-24.0pp	29.5%+37.6pp	-8.1%-10.0pp	1.9%+28.9pp	-26.9%-26.8pp	-0.1%
Return on Equity	1.8%-0.3pp	2.1%-0.5pp	2.7%-11.6pp	14.3%+19.8pp	-5.5%-6.7pp	1.2%+18.4pp	-17.2%-17.2pp	-0.1%
Return on Assets	1.0%-0.2pp	1.2%-0.3pp	1.5%-6.3pp	7.7%+10.2pp	-2.5%-3.0pp	0.5%+8.0pp	-7.5%-7.4pp	-0.0%
Current Ratio	2.08-0.1	2.15+0.1	2.010.0	2.02+0.2	1.82-0.1	1.93-0.2	2.12+0.0	2.09
Debt-to-Equity	0.250.0	0.26-0.0	0.27-0.0	0.29-0.3	0.56+0.0	0.53-0.1	0.62+0.1	0.56
FCF Margin	1.6%-3.2pp	4.8%-4.5pp	9.3%+12.9pp	-3.6%-6.6pp	3.0%-2.4pp	5.3%-4.5pp	9.8%+12.0pp	-2.1%

Similar Companies

Helen Of Troy Ltd HELE

$336.9M

Honest Company, Inc. HNST

$317.2M

Yatsen Hldg Ltd YSG

$286.3M

The Beauty Health Company SKIN

$115.7M

Spectrum Brands SPB

$1.7B

Frequently Asked Questions

What is Nu Skin Enter's annual revenue?

Nu Skin Enter (NUS) reported $1.5B in total revenue for fiscal year 2025. This represents a -14.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Nu Skin Enter's revenue growing?

Nu Skin Enter (NUS) revenue declined by 14.3% year-over-year, from $1.7B to $1.5B in fiscal year 2025.

Is Nu Skin Enter profitable?

Yes, Nu Skin Enter (NUS) reported a net income of $160.2M in fiscal year 2025, with a net profit margin of 10.8%.

What is Nu Skin Enter's EBITDA?

Nu Skin Enter (NUS) had EBITDA of $118.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Nu Skin Enter have?

As of fiscal year 2025, Nu Skin Enter (NUS) had $238.6M in cash and equivalents against $204.2M in long-term debt.

What is Nu Skin Enter's gross margin?

Nu Skin Enter (NUS) had a gross margin of 69.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Nu Skin Enter's operating margin?

Nu Skin Enter (NUS) had an operating margin of 4.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Nu Skin Enter's net profit margin?

Nu Skin Enter (NUS) had a net profit margin of 10.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Nu Skin Enter's return on equity (ROE)?

Nu Skin Enter (NUS) has a return on equity of 19.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Nu Skin Enter's free cash flow?

Nu Skin Enter (NUS) generated $46.0M in free cash flow during fiscal year 2025. This represents a -34.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Nu Skin Enter's operating cash flow?

Nu Skin Enter (NUS) generated $80.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Nu Skin Enter's total assets?

Nu Skin Enter (NUS) had $1.4B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Nu Skin Enter's capital expenditures?

Nu Skin Enter (NUS) invested $34.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Nu Skin Enter spend on research and development?

Nu Skin Enter (NUS) invested $10.8M in research and development during fiscal year 2025.

Does Nu Skin Enter buy back shares?

Yes, Nu Skin Enter (NUS) spent $20.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Nu Skin Enter have outstanding?

Nu Skin Enter (NUS) had 48M shares outstanding as of fiscal year 2025.

What is Nu Skin Enter's current ratio?

Nu Skin Enter (NUS) had a current ratio of 2.08 as of fiscal year 2025, which is generally considered healthy.

What is Nu Skin Enter's debt-to-equity ratio?

Nu Skin Enter (NUS) had a debt-to-equity ratio of 0.25 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Nu Skin Enter's return on assets (ROA)?

Nu Skin Enter (NUS) had a return on assets of 11.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Nu Skin Enter's Altman Z-Score?

Nu Skin Enter (NUS) has an Altman Z-Score of 3.66, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Nu Skin Enter's Piotroski F-Score?

Nu Skin Enter (NUS) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Nu Skin Enter's earnings high quality?

Nu Skin Enter (NUS) has an earnings quality ratio of 0.50x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Nu Skin Enter cover its interest payments?

Nu Skin Enter (NUS) has an interest coverage ratio of 4.7x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Nu Skin Enter?

Nu Skin Enter (NUS) scores 44 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.